An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

Phase 3 Active not recruiting 132 enrolled Viridian Therapeutics, Inc.

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).

Timeline

Start: 2024-08-27
Primary completion: 2026-02-12
Completion: 2026-11-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	VRDN-003	Monoclonal antibody	—	Subcutaneous

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

Summary

Timeline

Drugs

Indications